B
Braidwell Portfolio holdings
AUM
$2.92B
1-Year Est. Return
4.59%
1 Year Est. Return
-4.59%
AUM
$2.84B
AUM Growth
-$528M
(-16%)
Holding
86
Top Buys
| 1 | +$63.4M | |
| 2 | +$47.4M | |
| 3 | +$42.5M | |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$38.9M |
| 5 |
Krystal Biotech
KRYS
|
+$36.1M |
Top Sells
| 1 | +$64.8M | |
| 2 | +$43.2M | |
| 3 | +$39.6M | |
| 4 |
BioNTech
BNTX
|
+$35.3M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$33.1M |
Sector Composition
| 1 | Healthcare | 67.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Skye Bioscience
SKYE
$47.4M
| $1.31M | 0.05% |
825,732
|
|
||
52
Trevi Therapeutics
TRVI
$1.34B
| $453K | 0.02% |
+72,083
|
|
||
|
AVDL
53
Avadel Pharmaceuticals
AVDL
$1.83B
| – | – |
-4,105,726
|
|
||
|
54
BioNTech
BNTX
$24.8B
| – | – |
-309,865
|
|
||
55
Bruker
BRKR
$6.07B
| – | – |
-353,200
|
|
||
56
Candel Therapeutics
CADL
$277M
| – | – |
-1,600,000
|
|
||
57
Exact Sciences
EXAS
$12.5B
| – | – |
-353,000
|
|
||
58
4D Molecular Therapeutics
FDMT
$490M
| – | – |
-1,225,448
|
|
||
59
Geron
GERN
$683M
| – | – |
-7,006,315
|
|
||
60
Immatics
IMTX
$1.1B
| – | – |
-3,503,965
|
|
||
61
Jasper Therapeutics
JSPR
$49.7M
| – | – |
-714,658
|
|
||
62
Keros Therapeutics
KROS
$494M
| – | – |
-1,894,439
|
|
||
63
Vaxcyte
PCVX
$5.45B
| – | – |
-222,424
|
|
||
64
Protagonist Therapeutics
PTGX
$4.95B
| – | – |
-20,109
|
|
||
65
Arcus Biosciences
RCUS
$2.39B
| – | – |
-802,100
|
|
||
66
Viridian Therapeutics
VRDN
$2.62B
| – | – |
-34,094
|
|
||
|
CBLL
67
CeriBell Inc
CBLL
$444M
| – | – |
-210,000
|
|
||
|
FNA
68
DELISTED
Paragon 28, Inc.
FNA
| – | – |
-3,834,809
|
|
||
|
NVRO
69
DELISTED
NEVRO CORP.
NVRO
| – | – |
-1,698,768
|
|